Skip to content

Our Team

We are a mission-aligned team with expertise across human biology, immunology, chemistry, computational biology, data science, machine learning, drug development, clinical, and commercial leadership.

Our Purpose

We are drawn together by our shared purpose and relentless hunger to improve health outcomes for as many people as possible while reducing the growing chronic disease burden. Our approach to innovation is uniquely human-centered — unlocking connections between Anthromolecule™ chemistry and biological pathways driving disease to create solutions preferred by patients and clinicians that are designed to transform the treatment of disease.

We have brought together an inclusive, interdependently ambitious, and high-performing team with the courage to learn, iterate and make leaps together. We approach our work with humility, acknowledging and embracing the complexity of the disciplines we need to bring together and the many unknowns in human biology.


Board of Directors

  • Portrait of Noubar Afeyan, Ph.D.

    Noubar Afeyan, Ph.D.

    Co-Founder and Board Director
    Founder & CEO, Flagship Pioneering
  • Portrait of Margo Georgiadis

    Margo Georgiadis

    Co-Founder and CEO; Board Director
  • Portrait of Ignacio Martinez

    Ignacio Martinez

    Co-Founder and Board Director
    General Partner, Flagship Pioneering
  • Portrait of Lord Ara Darzi, M.D.

    Lord Ara Darzi, M.D.

    Chair of the Board
    Director of the Institute of Global Health Innovation at Imperial College London and Chair of Imperial College Health Partners; Honorary Consultant Surgeon at Imperial College Hospital NHS Trust
  • Portrait of Phyllis Yale

    Phyllis Yale

    Board Director
    Chair of the Board, Blue Cross Blue Shield of Massachusetts and Kindred Healthcare, Inc.; Board Member, Bristol-Myers Squibb; Former Senior Partner and Leader of Healthcare Practice, Bain & Company
  • Portrait of Andreas Fibig

    Andreas Fibig

    Board Director
    Former Chairman and CEO, International Flavors & Fragrances; Former Chairman and President, Bayer Healthcare Pharmaceuticals
  • Portrait of Michael Severino, M.D.

    Michael Severino, M.D.

    Board Director
    CEO, Tessera Therapeutics; Former Vice Chairman and President, Abbvie; Former SVP and CMO, Amgen
  • Portrait of David Khougazian

    David Khougazian

    Board Director
    Growth Partner, Flagship Pioneering
  • Portrait of Larry Hamann

    Larry Hamann

    Board Director
    Co-founder and CEO of Interdict Bio; Former Global Head, Drug Discovery Sciences, Takeda Pharmaceuticals
  • Portrait of Pietro Antonio Tataranni, M.D.

    Pietro Antonio Tataranni, M.D.

    Board Observer
    Chief Medical Officer, PepsiCo; Former SVP, Head of Medical Affairs, Diabetes and Cardiovascular, Sanofi
We are growing our team of individuals, looking to change the world.
View Open Positions


As boundary pushers, we are amassing the leading minds across disciplines to enable our success. We are grateful for our many distinguished advisors who challenge us every day to think bigger and smarter to achieve our mission.
  • Connor Coley, Ph.D.

    Assistant Professor of Chemical Engineering & Electrical Engineering and Computer Science, MIT
  • Jim Collins, Ph.D.

    Termeer Professor of Medical Engineering & Science, MIT; Core Founding Faculty Member, Wyss Institute, Harvard; Institute Member, Broad Institute of MIT and Harvard
  • Keith James, Ph.D.

    Former President, Ferring Research Institute, and Senior Vice-President and Head of Drug Discovery at Insitro and Pfizer
  • Iain McInnes, Ph.D., M.B.Ch.B

    Vice Principal and Head of College of Medical, Veterinary and Life Sciences, Muirhead Chair of Medicine, Versus Arthritis Professor of Rheumatology, University of Glasgow
  • Luke O'Neill, Ph.D.

    Professor and Chair of Biochemistry and Immunology, Trinity College
  • Paul Ridker, M.D.

    Eugene Braunwald Professor of Medicine, Harvard University and Brigham and Women's Hospital; Director of the Center for Cardiovascular Disease Prevention
  • Peter Sorger, Ph.D.

    Otto Krayer Professor of Systems Pharmacology, Head of the Harvard Program in Therapeutic Sciences (HiTS), Harvard Medical School; Cofounder, Merrimack Pharmaceuticals

Join Us

We are growing our team of leaders, committed to finding breakthroughs to make a difference in as many lives as possible.
View Open Positions

Contact Us

  • Partnerships

    We welcome the opportunity to partner with experts across areas who share our passion for creating Anthromolecule medicines and want to collaborate to accelerate the development of safe, efficacious and accessible therapies across diseases.
  • Press

    For media inquiries or the latest on research, thought leadership, company news, and events contact: